RIVIVE Trademark

Trademark Overview

On Wednesday, September 12, 2018, a trademark application was filed for RIVIVE with the United States Patent and Trademark Office. The USPTO has given the RIVIVE trademark a serial number of 88113597. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 2, 2022. This trademark is owned by Harm Reduction Therapeutics, Inc.. The RIVIVE trademark is filed in the Pharmaceutical Products category with the following description:

Naloxone intranasal spray product
rivive

General Information

Serial Number88113597
Word MarkRIVIVE
Filing DateWednesday, September 12, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 2, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 29, 2019

Trademark Statements

Goods and ServicesNaloxone intranasal spray product

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, September 19, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameHarm Reduction Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBethesda, MD 20814
Party NameHarm Reduction Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBethesda, MD 20814

Trademark Events

Event DateEvent Description
Monday, May 2, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 2, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 27, 2021SOU EXTENSION 5 GRANTED
Wednesday, September 22, 2021SOU EXTENSION 5 FILED
Monday, September 27, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 22, 2021TEAS EXTENSION RECEIVED
Thursday, February 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 23, 2021SOU EXTENSION 4 GRANTED
Tuesday, February 23, 2021SOU EXTENSION 4 FILED
Tuesday, February 23, 2021TEAS EXTENSION RECEIVED
Friday, August 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 26, 2020SOU EXTENSION 3 GRANTED
Wednesday, August 26, 2020SOU EXTENSION 3 FILED
Wednesday, August 26, 2020TEAS EXTENSION RECEIVED
Friday, March 13, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 11, 2020SOU EXTENSION 2 GRANTED
Wednesday, March 11, 2020SOU EXTENSION 2 FILED
Wednesday, March 11, 2020TEAS EXTENSION RECEIVED
Saturday, September 7, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 5, 2019SOU EXTENSION 1 GRANTED
Thursday, September 5, 2019SOU EXTENSION 1 FILED
Thursday, September 5, 2019TEAS EXTENSION RECEIVED
Tuesday, March 26, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 29, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 29, 2019PUBLISHED FOR OPPOSITION
Wednesday, January 9, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, December 22, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, December 22, 2018ASSIGNED TO EXAMINER
Wednesday, September 19, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM

Related Keywords

rivive product spray intranasal naloxone